Raptor Pharmaceutical Inc.'s PROCYSBI™ Now Commercially Available in the U.S. for Nephropathic Cystinosis Patients

Published: Jun 19, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NOVATO, Calif., June 19, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI™ (cysteamine bitartrate) delayed-release capsules are now available in the U.S. for shipment to cystinosis patients. The U.S. Food and Drug Administration (FDA) approved PROCYSBI on April 30, 2013 for the management of nephropathic cystinosis in adults and children ages 6 years and older. Initial prescription claims have been approved by multiple payor categories and PROCYSBI is being shipped to patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news